Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 901 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus Infection Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identification to Elimination in HCV-Infected Individuals

NCT03195205
View directory record Official record
Conditions
Hepatitis C
Interventions
OraQuick HCV Rapid Antibody Test
Diagnostic Test
Lead sponsor
TruCare Internal Medicine & Infectious Disease
Other
Eligibility
18 Years and older
Enrollment
3,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

NCT03235154
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 15, 2026, 10:27 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV

NCT01040039
View directory record Official record
Conditions
HIV Infections, Hepatitis C Virus
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

NCT02118012
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Chlorcyclizine HCl, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

NCT01250366
View directory record Official record
Conditions
HCV (Genotype 1)
Interventions
INX-08189, Placebo matching with INX-08189, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

NCT00833378
View directory record Official record
Conditions
Hepatitis C
Interventions
Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 15, 2026, 10:27 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers

NCT01274013
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
20 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 15, 2026, 10:27 PM EDT
Not yet recruiting Not applicable Interventional

Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs

NCT07631559
View directory record Official record
Conditions
HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders, Healthcare Access, Harm Reduction
Interventions
Partner navigation intervention booster session
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

NCT01726517
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 10:27 PM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

NCT00324389
View directory record Official record
Conditions
Hepatitis C
Interventions
Interferon alpha
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 15, 2026, 10:27 PM EDT
Withdrawn Phase 4 Interventional

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

NCT00782301
View directory record Official record
Conditions
Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
Interventions
maraviroc, etravirine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Clearwater, Florida • Orlando, Florida • Safety Harbor, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 15, 2026, 10:27 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

NCT01194037
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Genotype 1
Interventions
recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • National City, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

NCT01448044
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

NCT00735969
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 15, 2026, 10:27 PM EDT
Completed No phase listed Observational

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850
View directory record Official record
Conditions
Hepatitis C, Hepatitis B
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 10:27 PM EDT
Completed No phase listed Observational

Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes

NCT02650024
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

NCT02673489
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV, SOF, RBV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Chronic Hepatitis Intervention Project for Drug Users

NCT00596843
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
Motivational interviewing, Educational intervention
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 15, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 15, 2026, 10:27 PM EDT